Trius Therapeutics to Present Data From Drug Development Programs at ICAAC

SAN FRANCISCO, Sept. 5, 2012 (GLOBE NEWSWIRE) -- ICAAC 2012 -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that the results of multiple studies from its drug development programs, including its lead antibiotic drug candidate tedizolid phosphate (TR-701), will be presented in poster and podium presentations at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in San Francisco from September 9 to September 12, 2012.

Back to news